Drug delivery system are advanced engineered technologies used for the controlled release and targeted delivery of the therapeutic agents. Administering the drug locally rather than systemically would reduce the adverse effects while maximizing the treatment effects. Drug delivery systems has been changing drastically since past few decades and greater changes are anticipated in the future with the advancement in the biomedical engineering. The more targeted the drug is the less are the chances of developing drug resistance.
Gene delivery system is referred to as the process of introduction of foreign DNA into the host cell. Gene therapy consist of the insertion of the normal gene into a genome through a vector to replace the abnormal or disease causing gene. Gene delivery system should have the following three characteristics – vector should protect the transgene from nuclease enzyme. Should transport transgene from plasma membrane to target cell nucleus, should not have any toxic effects. A clear understanding of mechanism of interaction between the target cell and delivery system is required for the successful design of the gene delivery system. Recent advances in the field of molecular biology and r-DNA technology is changing the basis of the clinical research and drug and gene delivery system is extensively employed for treatment of cancer, cardiovascular diseases, liver diseases and auto-immune diseases.
Few of the market drivers for the drug and gene delivery system are emerging new and advanced technologies, increased investment on the R&D of drug delivery and gene delivery methods and better targeting and low dosing frequency. Growing demand for the self-administration and home healthcare devices is also fueling the growth of drug and gene delivery system market. However stringent regulatory process, technical barriers, increased drug recalls are few of the restraints for the drug and gene delivery market.
Based on the product type drug delivery system is segment into oral drug delivery system, transmucosal drug delivery system, inhalation/pulmonary drug delivery system, transdermal drug delivery system, injection-based drug delivery system, carrier based drug delivery system. Carrier based drug delivery system is further segmented into liposomal drug delivery system and nanoparticle drug delivery system
Based on technology drug delivery system are segmented into intrauterine implants, prodrug implants, polymeric drug delivery and targeted drug delivery
Based on the application the drug delivery system are segmented into infectious disease, oncology, ophthalmology, urology, diabetes, lung-specific drug delivery system, CNS drug delivery system.
Based on vector type gene delivery system is segmented into viral gene delivery system, non-viral gene delivery system and combined hybrid systems. Viral gene delivery system is further segmented into adenoviral delivery system, lentiviral gene delivery system, retrovirus gene delivery system, adeno-associated viral delivery system, sendai virus and herpes simplex viral delivery system. Non-viral gene delivery system is further segmented into natural organic compounds, physical methods and chemical methods. Natural organic compounds include naked DNA or plasmid DNA, physical method include electroporation, gene gun, sonoporation, magnetofection, ultrasound, hydrodynamic therapy. Chemical methods include polymers, electrostatic interaction, encapsulation, adsorption, liposomes, dendrimers, cationic lipid compatible systems and nanoparticle carriers
Based on geography the drug and gene delivery system is segmented into North America, Europe, Asia-Pacific, Latin America and Middle East & Africa. It is anticipated that North America would dominate the market due to advanced healthcare infrastructure, increased funding for research and development activities for drug and gene delivery system. Asia Pacific region is anticipated to grow significantly due to the vast untapped market, adaption of advanced delivery systems.
Key players are Johnson and Johnson, Pfizer, Inc., 3M company, Amgen Inc, Astrazeneca plc, Bayer AG, Baxter International Inc., F. Hoffmann-La Roche Ltd, Becton, Dickinson and Company Teva Pharmaceuticals, Boston Scientific and Novartis AG
Key players in the gene delivery systems market are Epeius Biotechnologies Corporation, SiBiono GeneTech Co., Human Stem Cells Institute, Unique N.V. and Shanghai Sunway Biotech Co., Ltd.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.
Note : All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Transparency Market Research.